Literature DB >> 32106369

LncRNA MFI2-AS1 promotes HCC progression and metastasis by acting as a competing endogenous RNA of miR-134 to upregulate FOXM1 expression.

Yongpeng Wei1, Zhuo Wang1, Yi Zong2, Dewu Deng3, Peiqin Chen4, Junhua Lu5.   

Abstract

Hepatocellular carcinoma (HCC) is worldwide accepted most common malignancies, as well as the second major cause of death among Chinese with cancer. There is an increasing evidence that could prove the potential effect of long non-coding RNAs (lncRNAs) to the biological performance of HCC. In present study, with high expression level in The Cancer Genome Atlas (TCGA) HCC samples, lncRNA MFI2 Antisense RNA 1 (MFI2-AS1) was closely related to poor prognosis and advanced stage among patients with HCC. In addition, up-regulation of MFI2-AS1 was further comfirmed in HCC tissues and HCC cell line. Ectopic expression of MFI2-AS1 stimulated the proliferation and metastasis of HCC cells, but knockdown MFI2-AS1 suppressed HCC cell proliferation and metastasis, indicating that MFI2-AS1 exerted oncogenic functions in the tumorigenesis of HCC. Simultaneously, compared with the negative control group, xenograft tumors in MFI2-AS1 group were characterized with poor growth, smaller volumes and less liver metastases. The post-transcriptional regulation of FOXM1 by MFI2-AS1 occured mechanistically, playing a role of competing with endogenous RNA (ceRNA) in HCC to sponge miR-134. Over-expression of MFI2-AS1 increased FOXM1 expression both at mRNA and protein level, whereas it was reducd by miR-134. Meanwhile, knockdown of miR-134 abolished the repression of shMFI2-AS1 on FOXM1 expression. Furthermore, we demonstrated that miR-134 reverses the impact of MFI2-AS1 on HCC proliferation and metastasis through regulation on FOXM1. Collectively, we determined that MFI2-AS1 crucially acted in HCC progression via functioning as miR-134 sponge to upregulating FOXM1 expression, and was conducive to the promotion of better understanding the direct diagnostics and iatreusiology of lncRNA in HCC.
Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Competing endogenous RNA; FOXM1; Hepatocellular carcinoma; MFI2-AS1; Metastasis; miR-134

Mesh:

Substances:

Year:  2020        PMID: 32106369     DOI: 10.1016/j.biopha.2020.109890

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  10 in total

1.  Copy number amplification and SP1-activated lncRNA MELTF-AS1 regulates tumorigenesis by driving phase separation of YBX1 to activate ANXA8 in non-small cell lung cancer.

Authors:  Xiyi Lu; Jing Wang; Wei Wang; Chenfei Lu; Tianyu Qu; Xuezhi He; Xinyin Liu; Renhua Guo; Erbao Zhang
Journal:  Oncogene       Date:  2022-05-04       Impact factor: 9.867

2.  MicroRNA-877-5p Inhibits Cell Progression by Targeting FOXM1 in Lung Cancer.

Authors:  Zhiguang Liu; Xinlian Wang; Liqiang Cao; Xiaowei Yin; Qian Zhang; Lan Wang
Journal:  Can Respir J       Date:  2022-06-15       Impact factor: 2.130

3.  Long Noncoding RNA ST7-AS1 Upregulates TRPM7 Expression by Sponging microRNA-543 to Promote Cervical Cancer Progression.

Authors:  Hongguo Qi; Lianwei Lu; Lili Wang
Journal:  Onco Targets Ther       Date:  2020-07-27       Impact factor: 4.147

4.  Identification of long non-coding RNA signatures for squamous cell carcinomas and adenocarcinomas.

Authors:  Suyan Tian; Mingbo Tang; Jialin Li; Chi Wang; Wei Liu
Journal:  Aging (Albany NY)       Date:  2020-12-09       Impact factor: 5.682

5.  Long Noncoding RNA FOXP4-AS1 Predicts Unfavourable Prognosis and Regulates Proliferation and Invasion in Hepatocellular Carcinoma.

Authors:  Jingchen Liang; Duo Wang; Guanhua Qiu; Xiaoqi Zhu; Junjie Liu; Hang Li; Pingping Guo
Journal:  Biomed Res Int       Date:  2021-02-01       Impact factor: 3.411

Review 6.  Hepigenetics: A Review of Epigenetic Modulators and Potential Therapies in Hepatocellular Carcinoma.

Authors:  Mohamed H Yousef; Hassan A N El-Fawal; Anwar Abdelnaser
Journal:  Biomed Res Int       Date:  2020-11-24       Impact factor: 3.411

Review 7.  FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer.

Authors:  Cassie Liu; Carter J Barger; Adam R Karpf
Journal:  Cancers (Basel)       Date:  2021-06-19       Impact factor: 6.639

8.  The pan-cancer lncRNA PLANE regulates an alternative splicing program to promote cancer pathogenesis.

Authors:  Liu Teng; Yu Chen Feng; Su Tang Guo; Pei Lin Wang; Teng Fei Qi; Yi Meng Yue; Shi Xing Wang; Sheng Nan Zhang; Cai Xia Tang; Ting La; Yuan Yuan Zhang; Xiao Hong Zhao; Jin Nan Gao; Li Yuan Wei; Didi Zhang; Jenny Y Wang; Yujie Shi; Xiao Ying Liu; Jin Ming Li; Huixia Cao; Tao Liu; Rick F Thorne; Lei Jin; Feng-Min Shao; Xu Dong Zhang
Journal:  Nat Commun       Date:  2021-06-18       Impact factor: 14.919

Review 9.  Role of long noncoding RNA-mediated competing endogenous RNA regulatory network in hepatocellular carcinoma.

Authors:  Zhao-Shan Niu; Wen-Hong Wang; Xian-Ning Dong; Li-Mei-Li Tian
Journal:  World J Gastroenterol       Date:  2020-08-07       Impact factor: 5.742

Review 10.  Role of Metastasis Suppressor KAI1/CD82 in Different Cancers.

Authors:  Wei Yan; Jinny Huang; Qian Zhang; Jian Zhang
Journal:  J Oncol       Date:  2021-07-09       Impact factor: 4.375

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.